Total recall of radiotherapy with mTOR inhibitors: A novel and potentially frequent side-effect?

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 485-486

  Bourgier, C ^a,b   Massard, C ^a   Moldovan, C ^a   Soria, J C ^a   Deutsch, E ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OXALIPLATIN; PACLITAXEL; TEMSIROLIMUS; TRASTUZUMAB;

ADULT; AGED; ANEMIA; BLADDER OBSTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COLITIS; DRUG INDUCED DISEASE; FEMALE; GASTRITIS; HISTOPATHOLOGY; HUMAN; LETTER; LIVER METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RECALL SYNDROME; STOMACH HEMORRHAGE; STOMACH ULCER; TELANGIECTASIA; THROMBOCYTOPENIA;

EID: 79251558792     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq741     Document Type: Letter

References (4)

1. Law AB, Junor EJ. Chemotherapy-induced recall of cetuximab and radiation skin reaction. Clin Oncol (R Coll Radiol) 2009; 21: 77-78.
2. Azria D, Magne N, Zouhair A et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31: 555-570.
3. Lordick F, Geinitz H, Theisen J et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006; 64: 1295-1298.
4. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008; 26: 2405-2406.